Financial Data and Key Metrics Changes - For Q4 2025, revenue was $12.5 million, roughly even compared to the previous year, with gross profit increasing to $3.4 million from $2.8 million in Q4 2024, resulting in a gross margin of 27% compared to 22% in the same period last year [4][5] - Full year 2025 revenue reached a record $62.1 million, up 18.6% from $51.9 million in 2024, while full year gross profit was $16.1 million, slightly down from $16.2 million in 2024 [5][6] - Adjusted EBITDA for 2025 was $4.2 million, less than 7% of revenue, with a target to improve EBITDA to double digits in 2026 [6][7] Business Line Data and Key Metrics Changes - The company launched 20 new brand partners in 2025, contributing to substantial revenue growth [5] - The operational challenges faced in 2025 included elevated labor costs, product design issues, and inventory control problems, which compressed margins [6][10] Market Data and Key Metrics Changes - The company anticipates a normalization of revenue in 2026, with a current shift in open orders at just under $33 million compared to $38 million a year ago [8][17] - The beauty sector remains resilient, with consumers viewing beauty as an affordable luxury, particularly in SPF-infused skincare [16] Company Strategy and Development Direction - The company initiated the "Transform and Transcend" strategy to enhance operational health and achieve a gross margin floor of 30% in 2026 [7][11] - The strategy focuses on operational excellence, technology-driven expansion, a new product development model, and collaborative globalization [12][14] - The company aims to leverage its patent portfolio to expand into adjacent prestige beauty segments and improve profitability [9][14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2026 will be a year focused on execution, addressing operational challenges to ensure sustainable profitability [17][41] - The company is optimistic about the future, expecting to stabilize its foundation in 2026 and set the stage for significant profitability in the following years [41] Other Important Information - The company has increased its patent portfolio by 20%, now totaling over 120 patents, which strengthens its market position [9] - The new product, Day Mode Hero Concealer, has been recognized in multiple categories, indicating strong market potential [10] Q&A Session Summary Question: Will EPS in 2026 be at or above the 2024 levels? - Management is not prepared to provide EPS guidance for 2026 but expects an increase in EBITDA to return to double digits [19][20] Question: What is the roadmap for growth to $200 million? - The company is addressing operational execution challenges and targeting growth in the fastest-growing market segments, with aspirations for higher profit margins [24][26] Question: Why has production struggled? - The company faced challenges due to simultaneous growth and the installation of new capabilities, but is confident in future performance improvements [34][35] Question: Did the company lose a brand partner? - Management clarified that there was no loss of any brand partner, but noted challenges with sell-through from one of their large mass-market customers [35][36] Question: Why did it take so long to schedule the call? - The call was scheduled after the year-end audit was completed, which is planned almost a year in advance [36]

Financial Data and Key Metrics Changes - For the fourth quarter, AirJoule Technologies reported net operating expenses of $3.2 million, with full-year net operating expenses at $13.6 million, up from $11.2 million in 2024, primarily due to a $4.2 million increase in non-cash stock-based compensation [28][29] - The net loss for the full year is $9 million, with a loss from investment in AirJoule JV of $39.3 million, compared to $5.3 million for the full year 2024 [29][30] - AirJoule Technologies ended 2025 with approximately $22 million in cash, and after a January 2026 equity offering, the combined cash position across AirJoule Technologies and the JV was approximately $44 million with no debt [31][32] Business Line Data and Key Metrics Changes - The company focused on technology validation, product development, and partnerships, achieving significant milestones in deploying AirJoule systems in various locations, including Texas, Arizona, California, and Dubai [8][9] - The AirJoule Core product, optimized for industrial dehumidification and water generation, is expected to be commercially available in late Q4 2026, while the larger AirJoule Prime system is currently under construction [19][20] Market Data and Key Metrics Changes - The Middle East is highlighted as a critical market due to its water stress, with Gulf nations relying on desalination for 70%-90% of their drinking water, creating a significant opportunity for AirJoule's distributed water generation technology [15][16] - The ongoing geopolitical conflicts have increased the urgency for water resilience, reinforcing the demand for AirJoule's solutions in the region [17] Company Strategy and Development Direction - The company aims to transition to a commercial pipeline in 2026, focusing on securing long-term customer commitments across various sectors, including data centers, industrial, defense, and international markets [13][14] - AirJoule's strategy includes leveraging partnerships, such as with GE Vernova and TenX, to accelerate commercialization and expand market access [11][12] Management's Comments on Operating Environment and Future Outlook - Management emphasized the growing urgency of water resilience due to environmental and geopolitical factors, positioning AirJoule's technology as a solution to these challenges [4][5] - The company expects 2026 to be a pivotal year for building customer relationships and deploying systems that will lay the groundwork for scaled commercial activity in 2027 and beyond [27][71] Other Important Information - The company has established a water purchase agreement business model, which has been well received by customers, and is expected to support long-term gross margins of 30%-35% at scale [50][56] - The company is actively engaged in customer outreach through direct engagement, warm introductions, and participation in conferences and trade shows [38][39] Q&A Session Summary Question: Customer engagement strategies - The company engages customers through direct outreach, warm introductions, and participation in industry events, with a focus on addressing urgent water needs in sectors like data centers [36][39] Question: Supply chain concerns - Most components are commercially available, with the only custom part being the sorbent chamber, which is produced at scale [40][41] Question: Capital expenditure needs for 2026 - The anticipated capital calls for the joint venture are part of the normal funding plan, with no major additional CapEx expected for 2026 [43][45] Question: Expected gross margins - Initial gross margins are less emphasized, with long-term targets of 30%-35% as the company transitions to contract manufacturing [50][51] Question: Competing with desalination - AirJoule's technology offers advantages in speed to market and water quality, despite desalination being cheaper in operating costs [53][54]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $32.4 million, a 3% increase from $31.5 million in Q4 2024, despite a $2 million revenue loss due to the early closure of the Companion Spine transaction [4][14] - Full year 2025 revenue reached $133.9 million, representing a 14% growth from $117.3 million in 2024 [7][16] - Adjusted EBITDA for Q4 2025 was $1.9 million, compared to approximately $0.4 million in Q4 2024, while full year adjusted EBITDA was $16.3 million, a significant improvement from a loss of $2.3 million in 2024 [19][16] - Net income for Q4 2025 was $57,000, or $0.00 per share, compared to a net loss of $3.2 million, or $0.02 per share in Q4 2024 [16] Business Line Data and Key Metrics Changes - The biologics product family was essentially flat in Q4 2025, with a focus on high-margin products expected to drive future growth [7][8] - Sales and marketing expenses for Q4 2025 were $10.9 million, down from $11.7 million in Q4 2024, primarily due to reduced commission expenses [15] - Research and development expenses decreased to $459,000 in Q4 2025 from $522,000 in Q4 2024 [15] Market Data and Key Metrics Changes - The company anticipates continued organic growth in its core biologics business, with expectations for revenue in 2026 to be between $95 million and $99 million [12] - The loss of license revenue from Q-Code and amniotic membrane agreements is expected to impact 2026 revenue, but the company is optimistic about ramping up its advanced wound care products [28][29] Company Strategy and Development Direction - The company has sharpened its focus on its core high-margin biologics business following the sale of non-core assets, which is seen as a transformational move [5][6] - Plans to double the number of regional sales representatives and expand the national accounts team are in place to drive institutional adoption and revenue growth [9][12] - The company is committed to maintaining positive free cash flow and does not anticipate the need for additional outside capital [5][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational discipline and the successful execution of strategic initiatives aimed at self-sustainability and cash flow generation [8][12] - The outlook for 2026 includes expectations for sequential quarter-over-quarter growth, driven by new product offerings and an expanded commercial organization [26] Other Important Information - The gross margin for Q4 2025 was 54.9%, an increase from 50.8% in Q4 2024, attributed to a favorable sales mix [14] - The company had $17.3 million in cash equivalents and restricted cash as of December 31, 2025, compared to $6.2 million a year earlier [20] Q&A Session Summary Question: Outlook for 2026 and organic growth in core biologics business - Management expects sequential quarter-over-quarter growth in 2026, with biologics in Q1 anticipated to be down low double digits compared to Q1 2025 due to headwinds from lost amnio product [26][27] Question: Impact of loss of license revenue from Q-Codes - The Q-Code revenue will completely go away, but management anticipates ramping up sales of their own branded products in advanced wound care as the year progresses [28][29] Question: Decline in hardware business throughout 2026 - A slow decline in the hardware business is expected throughout the year, with a projected decline approaching high teens percentage [31] Question: Growth drivers in biologics and distribution channels - Key growth drivers include advanced biologics products like OsteoVive Plus and CollagenX, with approximately 20-22% of growth expected from OEM channels [36][40] Question: Strategic thoughts on hardware business and gross margin in 2026 - Management is evaluating the hardware business as a potential strategic distraction but sees current offerings as strong. Gross margin for 2026 is expected to be in the low 60s percentage [46][48]

Financial Data and Key Metrics Changes - For the full year 2025, revenues reached $427 million, representing a 142% year-over-year increase from the prior year [13] - Gross profit increased by 340% to $96.3 million in 2025, up from $21.9 million in 2024, with gross profit margin expanding to 22.5% from 12.4% in 2024 [13][14] - EBITDA was $95.8 million in 2025, a 40% increase from $68.2 million in the prior year, while non-GAAP adjusted EBITDA was $110.8 million, up by 228% compared to $33.8 million for the same period in the prior year [15] - GAAP net income was $37.2 million for 2025, compared to $40.5 million for the same period last year, while adjusted net income was $52.2 million, compared to $6 million in 2024 [15][16] Business Line Data and Key Metrics Changes - The primary growth driver was a $241 million increase in solar cell sales, with an additional $7.6 million increase in module sales [13] - The company successfully shipped 2.3 gigawatts from Ethiopia to U.S. end customers and 1.9 gigawatts from Vietnam to international markets [6] Market Data and Key Metrics Changes - The company is positioned to meet the accelerating demand in the U.S. solar market, with shipment guidance for 2026 set between 5.5 and 5.8 gigawatts for solar cells and 1 to 1.3 gigawatts for solar modules [10][11] - The operational focus for 2026 includes maximizing existing infrastructure, particularly the Ethiopia cell facility and the Houston module facility [11] Company Strategy and Development Direction - The company aims to scale production continuously in 2026 and invest to expand capacity in Houston to 2 gigawatts [8] - The acquisition of the BridgeSun brand is intended to streamline operations and enhance growth without diluting shareholder value [9] - The company is committed to strengthening its supply chain by migrating sourcing of key components to the U.S. [9] Management's Comments on Operating Environment and Future Outlook - Management highlighted the successful navigation of a volatile trade environment and the establishment of a resilient foundation for future growth [5] - The company anticipates adjusted net income of approximately $90 million to $100 million for 2026, despite significant investments in R&D and technology [12] Other Important Information - The company generated cash flow from operations of $133 million in 2025, with $92 million of CapEx invested in manufacturing facilities [17] - The management team has been strengthened with the appointment of Rhone Resch as Chief Strategy Officer [2] Q&A Session Summary Question: Insights on gross margins with increased U.S. revenue share - Management indicated that they expect to maintain competitive margins as the Ethiopia facility operates at full capacity and the U.S. factory comes online [20][22] Question: Potential credits for Houston production capacity in 2026 - Management is cautious about providing guidance for Houston production but anticipates achieving 60%-70% utilization of the current 1 gigawatt capacity [25][26] Question: Future frequency of earnings calls - The company plans to report quarterly starting this year, with the first quarter numbers expected in May [27]

Financial Data and Key Metrics Changes - The company ended 2025 with a cash balance of $13.4 million, an increase from $4.6 million in the previous year, while operating costs decreased nearly 40% [14][20] - The net loss for Q4 2025 was $2.6 million or $0.56 per share, compared to $2.5 million or $0.62 per share for Q4 2024. For the full year, the net loss was $12.5 million or $2.93 per share, compared to $10.8 million or $2.86 per share in 2024 [20] Business Line Data and Key Metrics Changes - MiNK cells are currently in phase II clinical trials for solid tumor cancers and autoimmune inflammatory conditions, demonstrating durable survival beyond 23 months in heavily pretreated refractory cancers [3][6] - The company is advancing a trial in graft versus host disease (GVHD) and a phase II trial in gastric cancer, with results expected to be presented at a major conference in the first half of 2026 [4][11] Market Data and Key Metrics Changes - The company is targeting a significant patient population for hypoxemic pneumonia or ARDS, affecting approximately 200,000-300,000 patients annually, with a mortality rate of 30%-40% [8][10] - The company has observed substantial clinical activity in patients with severe acute respiratory distress, showing prolonged survival rates compared to hospital controls [9] Company Strategy and Development Direction - The company is focused on capital efficiency, combining disciplined internal execution with non-dilutive funding through government and institutional partnerships [5][12] - The strategic collaboration with the C-Further Consortium aims to advance the PRAME-targeted TCR-engineered iNKT program, reflecting external validation of the platform's maturity [13][14] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of generating clear, interpretable data to inform future development and regulatory pathways, with multiple readouts planned for the first half of 2026 [17][22] - The company is excited about the upcoming randomized controlled clinical trials and anticipates initial clinical data in the second half of 2026 [22] Other Important Information - The company has appointed Melissa Orilall as Principal Financial Officer to strengthen financial leadership and ensure alignment in capital allocation and operational execution [15] - The company has secured multiple sources of non-dilutive capital funding, including NIH funding and philanthropic support, to advance clinical programs without diluting shareholder equity [12][14] Q&A Session Summary Question: Can you discuss the phase II pneumonia and ARDS study and the control arm? - Management indicated that the trial will involve patients treated with standard of care, primarily steroid therapy, and that the cells will be added on top of this standard [25][26] Question: What is the status of the second-line gastric cancer trial? - Efficacy data from the gastric cancer trial is expected to be presented in the first half of 2026 at a major conference [31] Question: What differentiating aspects does the company consider for IPF and GVHD? - Management noted that the patient populations for ARDS will be specifically identified based on oxygenation and organ function, with no approved therapies currently available [35][38] Question: Can you clarify the combination approach with the IL-15 iNKT cell trial? - Management clarified that the company has not formally announced any collaboration regarding the IL-15 superagonist and will be public about any strategic collaborations in the future [46][48]

Financial Data and Key Metrics Changes - In 2025, B.O.S. achieved record revenues of $51 million, representing a 27% year-over-year growth, while net income increased by 57% to a record $3.6 million [2][4] - The company ended 2025 with a contracted backlog of $24 million, providing good visibility for the upcoming year [2] Business Line Data and Key Metrics Changes - The defense sector continues to drive growth in the supply chain and Robotics Division, with strong backlog visibility and customer relationships [3] - The RFID Division faced challenges due to geopolitical tensions in Israel, leading to goodwill impairment charges of $1.2 million in 2025 [4][7] Market Data and Key Metrics Changes - The USD to Israeli shekel exchange rate saw a 13% devaluation of the dollar against the shekel at the start of 2026, impacting operating expenses by an estimated $600,000 [6][7] - The company recognized $800,000 in non-recurring currency exchange income in 2025, which is not expected to repeat in 2026 [6][7] Company Strategy and Development Direction - B.O.S. is focusing on expanding its geographic reach, particularly in India, which is becoming a subcontracting hub for global defense programs [3] - The strategic plan for 2026 includes entering the hospital segment to reduce exposure to the Israeli civilian market, with expected revenue contributions starting in 2027 [4][5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the defense segment's growth despite ongoing geopolitical tensions, indicating that the war could positively affect the growth of the defense and Robotics divisions [13][14] - The company maintains a conservative outlook for 2026, projecting revenues and net income to remain at approximately $51 million and $3.6 million, respectively, while acknowledging the potential for upward revisions [9][16] Other Important Information - B.O.S. has a strong balance sheet with cash and equivalents growing to $11.8 million, and shareholders' equity increasing to nearly $29 million [7][9] - The company plans to shift its investor relations strategy towards digital marketing to enhance market awareness and visibility [10][11] Q&A Session Questions and Answers Question: Impact of ongoing war on business - Management indicated that the defense segment would likely benefit from prolonged conflict, while the RFID Division remains sensitive to geopolitical tensions [13][14] Question: Guidance for revenue growth - Management clarified that the guidance reflects a conservative approach, with a strong backlog supporting future growth potential [15][16] Question: M&A strategy and cash utilization - The company is evaluating several acquisition opportunities and plans to invest cash in securities until suitable M&A opportunities arise, with no expected dilution from acquisitions [17][20] Question: Revenue from India - Management confirmed that revenue from India averaged around $3 million over the past three years, with expectations for significant growth moving forward [22][54] Question: RFID investment in the hospital market - Initial investment in the hospital segment is expected to be around $200,000 in 2026, with profitability anticipated by 2028 [26][28] Question: Tax implications for 2026 - Management expects to utilize tax loss carryforwards, resulting in no significant tax expenses for 2026 [40][41]

Financial Data and Key Metrics Changes - The company ended 2025 with a cash balance of approximately $13.4 million, an increase from $4.6 million in the previous year [14] - The net loss for Q4 2025 was $2.6 million or $0.56 per share, compared to a net loss of $2.5 million or $0.62 per share in Q4 2024 [19] - For the full year, the net loss was $12.5 million or $2.93 per share, compared to $10.8 million or $2.86 per share in 2024, reflecting continued investment in clinical programs while controlling operational spending [19] Business Line Data and Key Metrics Changes - The company is advancing its MiNK iNKT cell platform, which is currently in phase II clinical trials for solid tumor cancers and autoimmune inflammatory conditions [3][4] - Clinical activity has been observed in patients with hypoxemic pneumonia, with a planned randomized phase II trial to begin soon [4][10] - The company has secured external funding for trials in graft versus host disease (GVHD) and gastric cancer, with results expected to be presented at major conferences [4][11] Market Data and Key Metrics Changes - The company is targeting a significant patient population for its hypoxemic pneumonia treatment, which affects approximately 200,000 to 300,000 patients annually with a mortality rate of 30%-40% [8][10] - The company is also focusing on the pediatric oncology market through its collaboration with the C-Further Consortium, which reflects external validation of its platform [13] Company Strategy and Development Direction - The company aims to restore immune function in various diseases, leveraging a capital-efficient model that combines internal execution with non-dilutive funding [5][12] - The strategy includes advancing clinical programs in immune-mediated diseases without incremental capital burden, supported by non-dilutive funding sources [12][14] - The company plans to initiate a randomized phase II/III study for ARDS and activate its GVHD trial in 2026, with initial clinical data expected in the second half of the year [17] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of demonstrating durability and mechanistic validation of their technology in 2025, setting the stage for future clinical advancements [21] - The company is focused on generating clear, interpretable data to inform development and regulatory pathways, with multiple readouts planned for 2026 [17] Other Important Information - The company appointed Melissa Orilall as Principal Financial Officer to strengthen financial leadership and ensure alignment in capital allocation and operational execution [15] - The company has seen increased external interest in its iNKT biology and is exploring strategic partnerships, although no formal collaborations have been announced yet [16][45] Q&A Session Summary Question: Can you discuss the phase II pneumonia and ARDS study, including patient numbers and control arms? - The company has not publicly posted the program details but will use physician's choice as the control arm, with the cells added on top of standard care [25][26] Question: What is the status of the second-line gastric cancer trial and when will efficacy data be available? - Efficacy data from the gastric cancer trial will be presented in the first half of the year at a major conference [30] Question: What differentiating aspects does the company consider for IPF and GVHD patient populations? - The company is focusing on immune-related conditions and has preclinical observations supporting the development of cells in IPF [34][36] Question: Can you clarify the IL-15 iNKT cell combination trial and its relation to the randomized controlled trial in ARDS? - The company has not formally announced any collaboration regarding the IL-15 superagonist and will provide updates when appropriate [44][45]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $16 million, representing a 4% decline year-over-year primarily due to lower system sales [19] - Full year 2025 revenue increased by 9% compared to 2024, with recurring revenue growing by 15% [21][22] - Gross margin for Q4 2025 was $6.9 million, representing a gross margin percentage of 43%, compared to 42% in Q4 2024 [23] - Full year gross margin was 46%, down from 48% in 2024, attributed to inflationary cost increases and tariffs [24] Business Line Data and Key Metrics Changes - The installed base of ALLY systems grew to approximately 200, up 48% year-over-year, with procedure volume increasing by 20% year-over-year in Q4 2025 [23] - Procedure volumes for the full year 2025 surpassed 206,000 globally, reflecting a 22% growth [23] - U.S. ALLY sales in Q4 2025 included 12 systems, an increase of 1 system from Q4 2024, while international sales dropped significantly [19][20] Market Data and Key Metrics Changes - Market share in the U.S. increased from 14% to 23.4% over 3.5 years, with significant gains from replacing first-generation lasers [10] - The company noted that nearly 50% of new systems in Q4 2025 were sold to femto-naive surgeons, expanding the market for laser-assisted cataract surgery [11] Company Strategy and Development Direction - The company aims to focus on growing procedure volumes and recurring revenue through additional system placements and increased utilization of existing systems [16] - Plans to re-engage with distributors and key stakeholders to regain momentum in international markets following the termination of the acquisition [15] - The company is exploring new market opportunities, including Australia and New Zealand, and intends to expand its presence in Europe and Southeast Asia [52][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to historical operating performance and emphasized the importance of rebuilding momentum over the next several quarters [9][26] - The termination of the merger was viewed as an opportunity to focus on independent growth and capitalize on market opportunities [66] - Management acknowledged the challenges faced during the acquisition process but highlighted the potential for long-term success and value creation [15][66] Other Important Information - The company received a $10 million transaction deposit following the termination of the merger, which will enhance cash flow [8][18] - Adjusted EBITDA for Q4 2025 was positive at $595,000, indicating operational cash flow positivity despite the challenges faced [25] Q&A Session Summary Question: Distributor commentary and growth re-acceleration - Management noted that while initial conversations with distributors have been positive, it will take several quarters to regain momentum in international markets due to previous uncertainties [30][33] Question: U.S. procedure growth and recurring revenue - Management indicated that U.S. procedure growth remains strong, with expectations for continued growth in recurring revenue as the installed base of systems increases [41][43] Question: Operating expenses and future projections - Management confirmed that cash-based operating expenses are expected to increase by no more than 10% in 2026, primarily focused on commercial activities [37][49]

Financial Data and Key Metrics Changes - For the year ended December 31, 2025, total revenue was approximately $54 million, down 18% from approximately $66 million in 2024, primarily due to lower contributions from healthcare operations [18] - Healthcare operations revenue was approximately $40 million in 2025, compared to approximately $52 million in 2024, with Q4 revenue of approximately $9 million stable compared to $10 million in Q3 [19] - Consolidated gross margin for the full year was approximately 20%, down from approximately 26% in 2024, but showed sequential improvement late in Q4 [21][22] Business Line Data and Key Metrics Changes - The healthcare segment represented about 73% of total revenue in 2025, generating nearly $40 million in sales, all from Florida [9] - A 94% increase in 340B contract revenue was reported in Q4 2025 compared to Q3 2025, driven by new business development and higher margin services [8][19] - E-commerce operations revenue increased to approximately $15 million, up 6% year-over-year, supported by strong demand for satellite connectivity and IoT products [20] Market Data and Key Metrics Changes - The healthcare segment is expanding from Florida to nationwide operations, leveraging a partnership with HealthWarehouse to support customers in all 50 states [4][9] - The e-commerce segment continues to grow, with new sales records set for IoT hardware and recurring high-margin airtime revenue [10] Company Strategy and Development Direction - The company is focused on improving operations, reducing costs, and driving profitability, with a strategic shift towards higher margin, recurring revenue streams [3][25] - The management team emphasizes the importance of maintaining Nasdaq listing as part of growth and expansion plans, which necessitated a reverse stock split [3][28] - The company aims to leverage its partnership with HealthWarehouse to create new revenue streams and expand its healthcare offerings nationally [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about early signs of margin improvement and reduced operating losses expected in the latter half of 2026 [7][25] - The company anticipates continued growth in 340B contract revenue and fulfillment services, with gradual improvement in prescription volumes [20][26] - Management highlighted the importance of cost optimization and strategic refocusing initiatives that are beginning to materialize in financial performance [18][25] Other Important Information - The company reported a significant reduction in operating expenses by approximately 25% to $20 million in 2025, compared to $26 million in 2024 [22] - The company ended the year with nearly $14 million in cash and no meaningful debt, providing flexibility for operations and growth investments [23] Q&A Session Summary Question: Was the reverse split necessary? - Management stated that the reverse split was necessary to maintain Nasdaq listing, as the buyback program expired and was not a viable option [27][28] Question: What are the current plans for the buyback? - Management is considering reinstating the buyback program and will announce details when appropriate [29] Question: What is the status of ongoing lawsuits? - Management is working with counsel to resolve remaining legal matters, with options to proceed to trial or reach a settlement [30]

Financial Data and Key Metrics Changes - For Q4 2025, revenue was $12.5 million, roughly even compared to the previous year, with gross profit of $3.4 million and a gross margin of 27%, up from 22% in Q4 2024 [4][5] - Full year 2025 revenue reached a record $62.1 million, up 18.6% from $51.9 million in 2024, while full year gross profit was $16.1 million, slightly down from $16.2 million in 2024 [5][6] - Adjusted EBITDA for 2025 was $4.2 million, less than 7% of revenue, with a target to improve EBITDA to double digits in 2026 [6][7] Business Line Data and Key Metrics Changes - The company launched 20 new brand partners in 2025, contributing to substantial revenue growth [5] - Transition costs and operational inefficiencies from facility consolidation impacted margins, with labor costs and inventory control being significant challenges [6][10] Market Data and Key Metrics Changes - The company anticipates a normalization period in revenue, with current open orders at just under $33 million compared to $38 million a year ago [9] - The beauty sector remains resilient, with consumers viewing beauty as an affordable luxury, particularly in SPF-infused skincare [16] Company Strategy and Development Direction - The "Transform and Transcend" initiative aims to enhance operational health and profitability, focusing on operational excellence, technology-driven expansion, product development, and collaborative globalization [12][14] - The company plans to establish a 30% gross margin floor as a target for 2026 and aims to increase free cash flow by improving procurement operations [7][8] Management's Comments on Operating Environment and Future Outlook - Management acknowledges challenges in operational execution due to rapid growth and emphasizes the need for improved efficiency to achieve sustainable profitability [11][17] - The company is optimistic about future growth, targeting a return to growth rates that exceed industry averages, driven by innovation and strategic partnerships [28][30] Other Important Information - The company increased its patent portfolio by 20%, now totaling over 120 patents, which strengthens its market position [10] - The new product, DayMode Hero Concealer, has received recognition in multiple categories, indicating strong market potential [10] Q&A Session Summary Question: Will EPS in 2026 be at or above 2024 levels? - Management is not prepared to provide EPS guidance but expects EBITDA to return to double digits in 2026 [20][21] Question: What is the roadmap to grow the company to $200 million? - The company is focused on addressing operational challenges and leveraging its innovation platform to resume growth at multiples of the industry's growth rate [27][29] Question: Are there plans for a dedicated investor call? - Management intends to improve communications and provide further information in the future [35] Question: Why has production struggled? - The company faced challenges due to simultaneous growth and the installation of new capabilities, impacting gross profit margins [36][37] Question: Did the company lose a brand partner? - Management clarified that there was no loss of a brand partner, but challenges were noted with sell-through from one of the mass-market customers [38] Question: Why did it take so long to schedule the call? - The call was scheduled post-year-end audit completion, which is planned almost a year in advance [39] Question: Will there be an improvement in sales this year? - Management anticipates a normalization period for sales but remains optimistic about future growth due to new leadership and partnerships [40][41]